Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 329.02% is 33% above its 1-year average of 247.73%, near the high end of its 1-year range (192.90%–329.02%).
As of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 329.02%.
RETURN ON EQUITY (ROE)
329.02%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+883.20%
vs the sector median at left
Market Cap
$34.50M
Return on Equity (ROE)
-44.50%
TTM Avg
-16.33%
3Y Avg
-36.34%
5Y Avg
-33.52%
Market Cap
$33.66M
Return on Equity (ROE)
-248.21%
TTM Avg
-991.58%
3Y Avg
-655.25%
5Y Avg
-438.62%
Market Cap
$33.55M
Return on Equity (ROE)
-117.97%
TTM Avg
-59.96%
3Y Avg
-42.92%
5Y Avg
-31.82%
Market Cap
$33.54M
Return on Equity (ROE)
-238.24%
TTM Avg
203.84%
3Y Avg
55.01%
5Y Avg
16.87%
Market Cap
$35.50M
Return on Equity (ROE)
-154.06%
TTM Avg
-1.75%
3Y Avg
68.54%
5Y Avg
60.27%
Market Cap
$35.57M
Return on Equity (ROE)
-161.63%
TTM Avg
-60.21%
3Y Avg
-26.37%
5Y Avg
-20.13%
Market Cap
$35.69M
Return on Equity (ROE)
N/A
TTM Avg
333.35%
3Y Avg
376.86%
5Y Avg
270.78%
Market Cap
$36.28M
Return on Equity (ROE)
-819.34%
TTM Avg
-116.46%
3Y Avg
-74.90%
5Y Avg
-96.78%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elutia Inc (ELUT) | $34.48M | 329.02% | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.50M | -44.50% | -16.33% | -36.34% | -33.52% |
| HeartBeam, Inc. (BEAT)vs › | $33.66M | -248.21% | -991.58% | -655.25% | -438.62% |
| Accuray Incorporated (ARAY)vs › | $33.55M | -117.97% | -59.96% | -42.92% | -31.82% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.54M | -238.24% | 203.84% | 55.01% | 16.87% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.50M | -154.06% | -1.75% | 68.54% | 60.27% |
| DocGo Inc. (DCGO)vs › | $35.57M | -161.63% | -60.21% | -26.37% | -20.13% |
| EUDA Health Holdings Limited (EUDA)vs › | $35.69M | N/A | 333.35% | 376.86% | 270.78% |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.28M | -819.34% | -116.46% | -74.90% | -96.78% |
| Rockwell Medical, Inc. (RMTI)vs › | $31.81M | -14.49% | -7.92% | -46.98% | -261.20% |
ROE
329.0%
ROA
118.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 329.02% |
| 2026-03-31 | 221.26% |
| 2025-12-31 | 192.90% |
